Abstract

This proposal is for continued support for the Pediatric Oncology Group Statistical Office. The capabilities of the office include the development of statistical considerations and design parameters for new protocols, implementation of mechanisms through which patients may be registered and the compilation, processing and analysis of data to answer protocol questions. The Statistical Office engages in methodologic research applied to cooperative study groups and randomized clinical trials. It assists the group in formulating research questions through analyses of risk factors, prognostic indicators or estimates of patient accrual. The staff of the office serve on all Pediatric Oncology Group committees with major administrative responsibilities, providing direction in specific disease, discipline and organizational aspects of the activities of the group. The Statistical Office also contributes to the quality assurance mechanisms implemented within the group and serves as a respository for patient files.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
2U10CA029139-06
Application #
3557032
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1980-12-01
Project End
1990-12-31
Budget Start
1986-02-01
Budget End
1986-12-31
Support Year
6
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
University of Florida
Department
Type
Schools of Arts and Sciences
DUNS #
073130411
City
Gainesville
State
FL
Country
United States
Zip Code
32611

  Publications

DuBois, Steven G; Mody, Rajen; Naranjo, Arlene et al. (2017) MIBG avidity correlates with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group. Pediatr Blood Cancer 64:
von Allmen, Daniel; Davidoff, Andrew M; London, Wendy B et al. (2017) Impact of Extent of Resection on Local Control and Survival in Patients From the COG A3973 Study With High-Risk Neuroblastoma. J Clin Oncol 35:208-216
Sankaran, Hari; Danysh, Heather E; Scheurer, Michael E et al. (2016) The Role of Childhood Infections and Immunizations on Childhood Rhabdomyosarcoma: A Report From the Children's Oncology Group. Pediatr Blood Cancer 63:1557-62
Lupo, Philip J; Danysh, Heather E; Plon, Sharon E et al. (2015) Family history of cancer and childhood rhabdomyosarcoma: a report from the Children's Oncology Group and the Utah Population Database. Cancer Med 4:781-90
Grufferman, Seymour; Lupo, Philip J; Vogel, Rachel Isaksson et al. (2014) Parental military service, agent orange exposure, and the risk of rhabdomyosarcoma in offspring. J Pediatr 165:1216-21
Tower, Richard L; Jones, Tamekia L; Camitta, Bruce M et al. (2014) Dose intensification of methotrexate and cytarabine during intensified continuation chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: POG 9406: a report from the Children's Oncology Group. J Pediatr Hematol Oncol 36:353-61
Mansour, Marc R; Abraham, Brian J; Anders, Lars et al. (2014) Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element. Science 346:1373-7
Schultz, K R; Devidas, M; Bowman, W P et al. (2014) Philadelphia chromosome-negative very high-risk acute lymphoblastic leukemia in children and adolescents: results from Children's Oncology Group Study AALL0031. Leukemia 28:964-7
Lupo, Philip J; Zhou, Renke; Skapek, Stephen X et al. (2014) Allergies, atopy, immune-related factors and childhood rhabdomyosarcoma: a report from the Children's Oncology Group. Int J Cancer 134:431-6
Schultz, K R; Carroll, A; Heerema, N A et al. (2014) Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia 28:1467-71

Showing the most recent 10 out of 268 publications